Floatz Rating
B60/100
Confidence
Indicative
Sponsor
UCB Biopharma SRL
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06315322CT.gov A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | — | Recruiting | — | — | — |
NCT05109234CT.gov A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Absence Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Brivaracetam Film-Coated (this asset) | UCB Biopharma SRL | P3 | B · 60 |
| Lamotrigine | Children's Hospital Medical Center, Cincinnati | P3 | BB |
| Ethosuximide | Children's Hospital Medical Center, Cincinnati | P3 | BB |
| Valproic Acid | Children's Hospital Medical Center, Cincinnati | P3 | B |
| Brivaracetam | UCB Biopharma SRL | P3 | B |
| Topiramate | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B |
| Npt 2042 | NeuroPro Therapeutics, Inc. | P2 | CCC |
| Flunarizine Hcl | University of British Columbia | P2 | CCC |
| Bmb-101 | Bright Minds Biosciences Pty Ltd | P2 | NR |
Other indications for Brivaracetam Film-Coated
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Juvenile Absence Epilepsy | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Brivaracetam Film-Coated in Childhood Absence Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/brivaracetam-film-coated-childhood-absence-epilepsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →